REG - Novacyt S.A. - Director/PDMR Shareholding

Novacyt SAAnnouncement

13/11/2020 18:05

RNS Number : 3414F
  
Novacyt S.A.
  
13 November 2020
  
 

Novacyt S.A.
 
("Novacyt" or the "Company")
 
Director/PDMR Shareholding
 
Paris, France and Camberley, UK - 13 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 13 November 2020, James McCarthy (PDMR), a corporate consultant, acquired 10,000 ordinary shares of €1/15 each in the Company at an average price of £8.953 per share.  The resultant beneficial shareholding of Mr McCarthy is 10,000 ordinary shares representing 0.01% of the Company's issued share capital.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
 



1.


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


 
James McCarthy
 




2.


Reason for the Notification




a)


Position/status


Corporate consultant and classified as a PDMR of the Company
 




b)


Initial notification/ Amendment


Initial Notification
 




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Novacyt S.A.




b)


LEI


213800BWAC2BF295EG28




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the Financial instrument, type of instrument


ordinary shares of €1/15 each
 








Identification code


FR0010397232




b)


Nature of the transaction


Acquisition of Ordinary Shares
 




c)


Price(s) and volume(s)


 



Price 


Volume




£8.848


1,130




£8.931


4,478




£9.001


4,320




£9.073


72








d)


Aggregated information:
· Aggregated volume
· Price


 



Price 


Volume




£8.953


10,000



 
 




e)


Date of the transaction


 
13 November 2020




f)


Place of the transaction


London Stock Exchange, AIM



 
 
 
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081 
 
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) 
+44 (0)20 3470 0470
 
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black 
+44 (0)20 7260 1000
 
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com
 
FTI Consulting (International) 
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com 
 
FTI Consulting (France)
Arnaud de Cheffontaines 
+33 (0)147 03 69 48 
arnaud.decheffontaines@fticonsulting.com 
 
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing.  The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide.  The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
 
For more information please refer to the website: www.novacyt.com
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHGPGMAGUPUGMW